3654 results for «392»

Filter By

3654 results

DCB in contemporary PCI: evidence, technique and physiology-guided decision-making

19 May 2026 – From EuroPCR 2026

This EuroPCR 2026 session explores the evolving role of drug-coated balloons (DCB) in contemporary PCI, highlighting how growing clinical evidence, refined procedural strategies and physiology-guided tools are reshaping everyday practice.

The discussion reviews the latest data supporting DCB use, including long-term outcomes from major registries and trials...

DCB in contemporary PCI: evidence, technique and physiology-guided decision-making

Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX

21 May 2026 – From EuroPCR 2026

This session explores the challenges of managing high thrombus burden in patients with acute coronary syndromes (ACS), with a focus on precision aspiration thrombectomy using the CAT RX device. Through case-based examples, it provides practical insights into procedural techniques and examines the role of CAT RX...

Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX

Evolving bifurcation treatment practices: DCB, angio-based FFR and side branch optimisation

19 May 2026 – From EuroPCR 2026

This EuroPCR 2026 session explores the evolving landscape of bifurcation PCI, focusing on drug-coated balloon (DCB) strategies, angio-based fractional flow reserve (FFR) and side branch optimisation. It highlights how new evidence and physiology-guided tools are reshaping decision-making in this complex lesion subset.

Discussions include insights from the...

Evolving bifurcation treatment practices: DCB, angio-based FFR and side branch optimisation

Artificial intelligence-driven precision therapy for TAVI: progress and practice in China

19 May 2026 – From EuroPCR 2026

This EuroPCR 2026 session explores the integration of artificial intelligence into precision therapy for TAVI in China, highlighting its growing role in procedural planning, optimisation and outcome prediction.

Through case-based discussion, it shows how AI-enabled tools can simulate valve deployment and visualise post-TAVR results, supporting more precise...

Artificial intelligence-driven precision therapy for TAVI: progress and practice in China

When less is better - Differentiated therapies to safely achieve TR 0-1+

19 May 2026 – From EuroPCR 2026

Therapeutic goals in tricuspid regurgitation are evolving, with increasing emphasis on achieving near-complete elimination of regurgitation (TR 0–1+) through differentiated transcatheter strategies.

This EuroPCR 2026 session explores how transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) can be used in a complementary way to reach...

When less is better - Differentiated therapies to safely achieve TR 0-1+

Real world practice inspiring new evidence generation in structural heart

21 May 2026 – From EuroPCR 2026

This LIVE case session showcases real-world clinical practice driving new evidence in structural heart interventions, with a focus on TAVI. It features expert insights into pre-procedural imaging and sizing, treatment strategies, procedural techniques, and post-procedural management. The session also introduces the novel Myval Octapro+ transcatheter heart...

Real world practice inspiring new evidence generation in structural heart

The microcirculation: the next frontier in coronary practice

18 May 2026 – From EuroPCR 2026

Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.

Left main and complex bifurcation stenting

21 May 2026 – From EuroPCR 2026

This focused session explores optimal strategies for treating left main and complex bifurcation coronary lesions, a setting that remains both anatomically and technically demanding.

It highlights the role of intracoronary imaging in refining procedural planning and optimising stenting strategy and technique. The discussion also reviews the mechanical...

Left main and complex bifurcation stenting

Why hypertension is a major unresolved problem

02 Oct 2024

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Sofie Brouwers

Author

Sofie Brouwers
Why hypertension is a major unresolved problem

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

TRISCEND II: Two-year outcomes of transcatheter tricuspid valve replacement for severe tricuspid regurgitation

31 Mar 2026

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Jonathan Curio

Author

Jonathan Curio
TRISCEND II: Two-Year Outcomes Of Transcatheter Tricuspid Valve Replacement For Severe Tricuspid Regurgitation

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

23 Jan 2025

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Author

Hector Garcia-Garcia
Jorge Sanz Sanchez

Author

Jorge Sanz-Sanchez
Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
Didn’t find what you were looking for?